Table 5.

Two-year overall survival and response rates of 66 patients with MDS and sAML with 20–29% BM blasts treated with azacitidine ± DLI for relapse after allo-HSCT according to the proposed scoring system.

Risk Score/Group	Response Rate (CR) after Azacitidine	2-y OS Rate after Azacitidine [±SEM]
1 (n = 13)	69%	67% ± 19%
2 (n = 32)	50%	38% ± 10%
3 (n = 21)	10%	18% ± 11%
	p = 0.0009	p = 0.0023

Note: allo-HSCT, allogeneic hematopoietic stem cell transplantation; AML, acute myeloid leukemia; BM, bone marrow; CR, complete remission; DLI, donor lymphocyte infusion; MDS, myelodysplastic syndrome; OS, overall survival; sAML, secondary AML; SEM, standard error of the mean; y, year.